Live from the NIH registry
Studies recruiting near Davenport right now
Top 25 of 45 recruiting studies, sorted by proximity — each links to its official registry page
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Refractory Differentiated Thyroid Gland Carcinoma
Phase 3
Interventional 264 participants sought
University of Iowa Healthcare Cancer Services Quad Cities — Bettendorf, Iowa (5.1 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
FastWire REvascularisation of Extremities, (For LOWer Limbs) - FREEFLOW
Chronic Total Occlusion of Artery of the Extremities
N/A
Interventional 65 participants sought
Vascular Institute of the Midwest — Davenport, Iowa (2.7 mi)
· Sponsor: Versono Medical Ltd
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Phase 3
Interventional 228 participants sought
Trinity Medical Center — Moline, Illinois (5.8 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma
Phase 3
Interventional 382 participants sought
University of Iowa Healthcare Cancer Services Quad Cities — Bettendorf, Iowa (5.1 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Multiple conditions
Phase 2
Interventional 314 participants sought
University of Iowa Healthcare Cancer Services Quad Cities — Bettendorf, Iowa (5.1 mi)
· Sponsor: National Cancer Institute (NCI)
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Atherosclerotic Cardiovascular Disease, Overweight
Phase 3
Interventional 12,800 participants sought
Midwest Cardiovascular Research Foundation — Davenport, Iowa (2.7 mi)
· Sponsor: Amgen
Extensively Hydrolyzed Formula Growth Monitioring Study (GMS)
Growth
N/A
Interventional 214 participants sought
Mid Valley Research Inc. — Moline, Illinois (5.8 mi)
· Sponsor: Mead Johnson Nutrition
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
Phase 3
Interventional 600 participants sought
University of Iowa Healthcare Cancer Services Quad Cities — Bettendorf, Iowa (5.1 mi)
· Sponsor: National Cancer Institute (NCI)
The Fourth Left Atrial Appendage Occlusion Study
Atrial Fibrillation, Stroke, Ischemic
N/A
Interventional 4,000 participants sought
Cardiovascular Medicine, PLLC and Unity Point Trinity Rock Island — Rock Island, Illinois (3.5 mi)
· Sponsor: Hamilton Health Sciences Corporation
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer
Phase 3
Interventional 590 participants sought
University of Iowa Health Care Cancer Services Quad Cities — Bettendorf, Iowa (5.1 mi)
· Sponsor: Revolution Medicines, Inc.
E-Mindfulness Approaches for Living After Breast Cancer
Breast Cancer, Depression
Phase 3
Interventional 402 participants sought
University of Iowa Healthcare Cancer Services Quad Cities — Bettendorf, Iowa (5.1 mi)
· Sponsor: NRG Oncology
EVERO Drug-coated Balloon (DCB) Randomized Trial
Peripheral Vascular Disease, Peripheral Arterial Disease
N/A
Interventional 410 participants sought
Midwest Cardiovascular Research Foundation — Davenport, Iowa (2.7 mi)
· Sponsor: Cook Research Incorporated
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC)
Phase 3
Interventional 1,040 participants sought
University of Iowa Healthcare Cancer Services Quad Cities — Bettendorf, Iowa (5.1 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Smoldering Plasma Cell Myeloma
Phase 3
Interventional 288 participants sought
University of Iowa Healthcare Cancer Services Quad Cities — Bettendorf, Iowa (5.1 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Anatomic Stage II Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Phase 3
Interventional 1,295 participants sought
University of Iowa Healthcare Cancer Services Quad Cities — Bettendorf, Iowa (5.1 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Phase 3
Interventional 3,680 participants sought
Trinity Medical Center — Moline, Illinois (5.8 mi)
· Sponsor: National Cancer Institute (NCI)
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
Chickenpox
Phase 3
Interventional 1,840 participants sought
GSK Investigational Site — Moline, Illinois (5.8 mi)
· Sponsor: GlaxoSmithKline
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
Hematopoietic and Lymphoid Cell Neoplasm, Immune System Disorder
N/A
Observational 2,240 participants sought
MercyOne Genesis Davenport Medical Center — Davenport, Iowa (2.7 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Obesity, Heart Failure
Phase 3
Interventional 5,610 participants sought
Midwest Cardiovascu Rsrch Foundation — Davenport, Iowa (2.7 mi)
· Sponsor: Novo Nordisk A/S
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Breast Cancer
Phase 3
Interventional 3,960 participants sought
University of Iowa Healthcare Cancer Services Quad Cities — Bettendorf, Iowa (5.1 mi)
· Sponsor: NRG Oncology
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Phase 3
Interventional 2,400 participants sought
University of Iowa Healthcare Cancer Services Quad Cities — Bettendorf, Iowa (5.1 mi)
· Sponsor: SWOG Cancer Research Network
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Stage III Colon Cancer
Phase 2, Phase 3
Interventional 1,912 participants sought
University of Iowa Healthcare Cancer Services Quad Cities — Bettendorf, Iowa (5.1 mi)
· Sponsor: NRG Oncology
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Plasma Cell Myeloma
Phase 3
Interventional 510 participants sought
University of Iowa Healthcare Cancer Services Quad Cities — Bettendorf, Iowa (5.1 mi)
· Sponsor: SWOG Cancer Research Network
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Phase 3
Interventional 1,524 participants sought
Trinity Medical Center — Moline, Illinois (5.8 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Multi-Center Registry for Peripheral Arterial Disease Interventions and Outcomes
Peripheral Arterial Disease
N/A
Observational 14,000 participants sought
Mid West Cardiovascular Research Foundation — Davenport, Iowa (2.7 mi)
· Sponsor: Baylor Research Institute